This startup fatigue can stem from a few different factors
GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors GLP-1 receptor agonists, sodium glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors reduce the risk of MACE compared to placebo
Parmar, R
We find that patients benefit from at least a 12-month comprehensive weight-loss program to establish the proper habits to sustain long-term weight loss If you are not a good candidate for GLP-1 agonists, our physicians will offer different modalities of weight loss for you, including alternative medications, lifestyle modification, continuous glucose monitoring, and other tools that we use as a part of our weight loss program in East Bakersfield, California
However, as this was an observational target trial emulation conducted in a predominantly male Veterans Affairs population, the results support but do not establish causality and may have limited generalisability to broader populations, particularly women and non-veteran groups